Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,946 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Participant Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

NCT01414881
View directory record Official record
Conditions
Healthy Volunteer
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

NCT00760565
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
RO4905417, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Gainesville, Florida • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271
View directory record Official record
Conditions
Healthy
Interventions
Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

NCT04663464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
abaloparatide-sMTS, abaloparatide-SC
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

NCT05755932
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
HFO-1234ze(E), HFA-134a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

NCT00649181
View directory record Official record
Conditions
Healthy
Interventions
Metolazone Tablets 5 mg, Zaroloxyn® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300
View directory record Official record
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers

NCT06167707
View directory record Official record
Conditions
Heart Failure, Fluid Overload
Interventions
SCP-111, Furosemide USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Throwing Device Tracker for Youth Injury Prevention

NCT04098107
View directory record Official record
Conditions
Overuse Injury
Interventions
Throwing Device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 14 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

NCT05581992
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 510, Omeprazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers

NCT04674709
View directory record Official record
Conditions
Flu-like Symptoms
Interventions
Oleander 4X - single, Oleander 4X - double, Oleander 4X - quadruple, Placebo
Drug
Lead sponsor
Avila Herbals
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers

NCT02256930
View directory record Official record
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, Sodium lauryl sulfate, Saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections

NCT07811999
View directory record Official record
Conditions
Healthy Participants
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

NCT01913314
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[^14C]-LY2835219
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

NCT00650364
View directory record Official record
Conditions
Healthy
Interventions
Midodrine HCl Tablets 5 mg, ProAmatine® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792
View directory record Official record
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611
View directory record Official record
Conditions
Healthy
Interventions
Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

NCT01900587
View directory record Official record
Conditions
Healthy
Interventions
Tapentadol ER Tamper-resistant Formulation (TRF), Tapentadol ER Prolonged-Release 2 (PR2)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 19, 2026, 12:32 PM EDT